Switch theme
Sign up to access all valuation multiples
Susmed Inc is engaged in the development of medical equipment and software systems Collection and distribution of medical information.
2015
n/a
LTM Revenue $2.3M
LTM EBITDA n/a
$26.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Susmed has a last 12-month revenue of $2.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Susmed achieved revenue of $2.3M and an EBITDA of -$2.4M.
Susmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Susmed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.5M | $2.3M | XXX | XXX | XXX |
| Gross Profit | $2.0M | $3.5M | XXX | XXX | XXX |
| Gross Margin | 58% | 153% | XXX | XXX | XXX |
| EBITDA | -$0.3M | -$2.4M | XXX | XXX | XXX |
| EBITDA Margin | -8% | -105% | XXX | XXX | XXX |
| Net Profit | -$1.6M | -$0.3M | XXX | XXX | XXX |
| Net Margin | -44% | -15% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Susmed's stock price is JPY 510 (or $3).
Susmed has current market cap of JPY 8.6B (or $57.0M), and EV of JPY 4.0B (or $26.7M).
See Susmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.7M | $57.0M | XXX | XXX | XXX | XXX | $-0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Susmed has market cap of $57.0M and EV of $26.7M.
Susmed's trades at 11.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Susmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Susmed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $26.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSusmed's NTM/LTM revenue growth is -100%
Susmed's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Susmed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Susmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Susmed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -35% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 739% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 132% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 71% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 203% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Susmed acquired XXX companies to date.
Last acquisition by Susmed was XXXXXXXX, XXXXX XXXXX XXXXXX . Susmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Susmed founded? | Susmed was founded in 2015. |
| Where is Susmed headquartered? | Susmed is headquartered in Japan. |
| Is Susmed publicy listed? | Yes, Susmed is a public company listed on TKS. |
| What is the stock symbol of Susmed? | Susmed trades under 4263 ticker. |
| When did Susmed go public? | Susmed went public in 2021. |
| Who are competitors of Susmed? | Similar companies to Susmed include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of Susmed? | Susmed's current market cap is $57.0M |
| What is the current revenue of Susmed? | Susmed's last 12-month revenue is $2.3M. |
| What is the current EV/Revenue multiple of Susmed? | Current revenue multiple of Susmed is 11.7x. |
| What is the current revenue growth of Susmed? | Susmed revenue growth between 2023 and 2024 was -35%. |
| Is Susmed profitable? | Yes, Susmed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
